Loading...
01/09 22:51
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial metrics, a positive outlook on product development, and strategic market positioning. Despite concerns about tariffs and Medicaid cuts, the company is mitigating risks through supply chain resiliency and innovative solutions. Guidance remains optimistic, particularly with the potential growth of OmniSphere and IV compounding products. The market cap indicates a more pronounced reaction, suggesting a positive stock movement in the short term.
Total Revenue $291 million, representing an increase of $14 million or 5% over the second quarter of 2024 and an increase of $21 million or 8% compared to the previous quarter. The increase was driven by growth in all four major product categories, including connected devices, technical services, SaaS and expert services, and consumables.
Product Revenue $163 million, representing an increase of $7 million compared to the second quarter of 2024 and an increase of $18 million over the previous quarter. The growth was attributed to stronger-than-expected revenues from connected devices, including contributions from lease renewals and consumables.
Service Revenue $127 million, which increased by $7 million from the second quarter of 2024 and represented an increase of $3 million over the previous quarter. The increase was due to higher service contract renewals and software subscriptions.
Non-GAAP Gross Margin 44.7%, representing an increase of 50 basis points compared to the second quarter of 2024 and an increase of 260 basis points from the prior quarter. The improvement was driven by higher product revenue volumes, favorable pricing, customer and product mix, and lower seasonal expenses.
GAAP Earnings Per Share (EPS) $0.12 per share compared to $0.08 per share in the second quarter of 2024 and a loss of $0.15 per share in the prior quarter. The improvement was driven by higher revenues and prudent expense management.
Non-GAAP Earnings Per Share (EPS) $0.45 compared to $0.51 per share in the same period last year and $0.26 per share in the prior quarter. The decline year-over-year was due to increased costs, while the quarter-over-quarter improvement was driven by higher revenues.
Non-GAAP EBITDA $38 million compared to $40 million in the same period last year and $24 million in the prior quarter. The year-over-year decline was due to increased costs, while the quarter-over-quarter improvement was driven by higher revenues.
Cash and Cash Equivalents $399 million as of June 30, 2025, compared to $387 million as of March 31, 2025. The increase was due to solid free cash flow generation.
Free Cash Flow $27 million during the second quarter of 2025, representing an increase of $17 million compared to the prior quarter. The improvement was driven by higher revenues and effective working capital management.
Days Sales Outstanding (DSO) 75 days for the second quarter of 2025, representing a decrease of 11 days compared to the prior quarter. The improvement was due to better collections.
Inventories $106 million as of June 30, 2025, an increase of $15 million from the prior quarter and an increase of $13 million from June 30, 2024. The increase was due to higher production levels to meet customer demand.
OmniSphere: A cloud-native platform designed to provide enterprise-wide visibility into medications and medical supplies inventory. It received HITRUST CSF i1 certification, affirming its cybersecurity and operational excellence.
MedVision: A software solution launched to manage real-time medication inventory workflows in clinics, offering dynamic dashboards, insights into stockouts, and automated reordering.
MedTrack - OR: An RFID-enabled product designed to work with Omnicell anesthesia workstations for automatic tracking of non-controlled medications in operating rooms.
Market Expansion: Focused on capturing greater market share across inpatient and outpatient settings, including nursing units, operating rooms, and pharmacies. Recent wins include a large Northeast health organization and other healthcare entities in Nebraska, Pennsylvania, New York, and government facilities.
Customer Wins: Highlighted strong demand for XT Amplify and XTExtend, contributing to significant portfolio deals and adoption in various regions.
Recurring Revenue Growth: Actions taken to grow predictable recurring revenue through service contracts, software subscriptions, and cloud-based offerings.
Innovation Lab: Opened a lab in Austin, Texas, for rapid prototyping and testing of customer-identified pain points.
Transformation Strategy: Evolving from a device-centric company to an end-to-end medication and medical supplies management technology platform, combining automation and intelligence.
Tariff Mitigation: Implemented pricing strategies and other initiatives to offset tariff impacts, with expected benefits in 2026.
Tariff Impact: The company is facing significant headwinds from tariffs, with a net impact of approximately $15 million expected for 2025. This includes $32 million in gross tariff impact, partially offset by mitigation efforts. The quarterly impact is projected to be $6 million for the third and fourth quarters of 2025. These tariffs are affecting profitability and require ongoing mitigation strategies, including pricing adjustments.
Macroeconomic Uncertainty: The company acknowledges uncertainty in the macroeconomic environment, which could impact customer demand and financial performance. Legislative and economic challenges are noted as potential risks.
Dynamic Cost Structure: The company is navigating a dynamic cost structure environment, which includes challenges related to tariffs and other cost pressures. This could impact margins and overall financial performance.
Supply Chain Resilience: Efforts to improve supply chain resilience are ongoing, but challenges remain in ensuring continuity of products, reducing costs, and enhancing efficiencies. These issues are critical to mitigating the impact of tariffs and other disruptions.
Nonrecurring Software Upgrade Costs: The company expects nonrecurring software upgrade costs in the field to impact non-GAAP EBITDA and earnings per share guidance for the third quarter of 2025.
Interest Income Reduction: A reduction in interest income due to repurchasing convertible senior notes in 2024 is creating a $0.20 headwind to non-GAAP earnings per share in 2025.
Full Year 2025 Guidance: Omnicell reaffirmed its full-year 2025 outlook for product bookings and annual recurring revenue (ARR). The company modestly increased its guidance for total revenues, non-GAAP EBITDA, and non-GAAP earnings per share, reflecting strong first-half performance and improved visibility for the remainder of the year.
Revenue Projections: Total revenues for full-year 2025 are now expected to be in the range of $1.13 billion to $1.16 billion, up from the prior guidance of $1.105 billion to $1.155 billion.
Non-GAAP EBITDA: Non-GAAP EBITDA for full-year 2025 is projected to be between $130 million and $145 million, an increase from the previous guidance of $120 million to $145 million.
Non-GAAP Earnings Per Share: Non-GAAP earnings per share for full-year 2025 are expected to range from $1.40 to $1.65, up from the prior expectation of $1.30 to $1.65.
Third Quarter 2025 Guidance: Total revenues are expected to be between $290 million and $300 million. Product revenues are anticipated to range from $165 million to $170 million, while service revenues are projected to be between $125 million and $130 million. Non-GAAP EBITDA is expected to be between $28 million and $32 million, and non-GAAP earnings per share are projected to range from $0.30 to $0.37.
Tariff Impact: The net quarterly impact of tariffs is expected to be approximately $6 million per quarter for the third and fourth quarters of 2025. The total net tariff impact for 2025 is projected to be around $15 million, with mitigation efforts expected to reduce the impact in 2026.
Future Growth Drivers: Omnicell expects future growth to be driven by expanding market presence, scaling recurring revenue, and accelerating its technology platform, OmniSphere. The company is focused on capturing greater market share across inpatient and outpatient settings, growing its predictable recurring revenue base, and advancing its cloud-native platform for enterprise-wide visibility into medication and medical supplies inventory.
New Product Launches: Omnicell launched MedVision, a software solution for real-time medication inventory workflows in clinics, and MedTrack - OR, an RFID-enabled product for operating rooms. These innovations aim to enhance visibility and operational efficiency in healthcare settings.
Stock Repurchase Program: During the second quarter of 2025, the Board of Directors authorized a new stock repurchase program of up to $75 million. As of June 30, 2025, the company has bought back approximately $16 million worth of its stock. The company plans to continue buying back shares of its common stock opportunistically.
The earnings call reveals strong financial performance with increased guidance, new product launches, and strategic growth drivers. Despite slight margin declines and cash flow reduction, the company has managed debt well and engaged in stock repurchases. The Q&A highlights positive sentiment towards AI and robotics integration, and a favorable buying environment in hospitals. The reaffirmed guidance and strategic focus on innovative platforms suggest a positive outlook, likely resulting in a 2% to 8% stock price increase given the market cap.
The earnings call highlights strong financial metrics, a positive outlook on product development, and strategic market positioning. Despite concerns about tariffs and Medicaid cuts, the company is mitigating risks through supply chain resiliency and innovative solutions. Guidance remains optimistic, particularly with the potential growth of OmniSphere and IV compounding products. The market cap indicates a more pronounced reaction, suggesting a positive stock movement in the short term.
The earnings call reveals several concerns: a significant tariff impact on financial projections, a reduction in EBITDA and EPS guidance, and declining margins. Despite strong revenue growth and strategic product development, the reduction in guidance due to tariffs and uncertainties in supply chain adjustments weigh negatively. The Q&A indicates management's evasiveness on key issues, adding to the market's uncertainty. Given the company's small market cap, the stock may react more strongly to these negative factors, leading to a likely decline in stock price over the next two weeks.
The earnings call presents a mixed picture: strong revenue growth YoY but a decline QoQ due to seasonality. The guidance is cautious, with flat to modest declines in bookings and revenue. The share repurchase is a positive, but tariff impacts and supply chain concerns weigh on sentiment. The Q&A reveals uncertainty around tariffs and supply chain adjustments, but no slowdown in demand. Given the market cap, the stock is likely to experience a neutral reaction, with the positive and negative factors balancing each other out.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
